Dateline City:
KENILWORTH, N.J.
Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More)
KENILWORTH, N.J.--(BUSINESS WIRE)--
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA (pembrolizumab), the companys
anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at
18 months compared to standard of care chemotherapy (docetaxel) in
patients with metastatic non-small cell lung cancer (NSCLC) previously
treated with platinum-containing chemotherapy whose tumors expressed
PD-L1 (tumor proportion score [TPS] of one percent or more), as well as
patients with high levels
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more